IBDEI108 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16154,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16154,1,3,0)
 ;;=3^PostProcedural Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,16154,1,4,0)
 ;;=4^E89.2
 ;;^UTILITY(U,$J,358.3,16154,2)
 ;;=^5003037
 ;;^UTILITY(U,$J,358.3,16155,0)
 ;;=E89.6^^88^872^29
 ;;^UTILITY(U,$J,358.3,16155,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16155,1,3,0)
 ;;=3^PostProcedural Adrenocortical Hypofunction
 ;;^UTILITY(U,$J,358.3,16155,1,4,0)
 ;;=4^E89.6
 ;;^UTILITY(U,$J,358.3,16155,2)
 ;;=^5003042
 ;;^UTILITY(U,$J,358.3,16156,0)
 ;;=L68.0^^88^872^6
 ;;^UTILITY(U,$J,358.3,16156,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16156,1,3,0)
 ;;=3^Hirsutism
 ;;^UTILITY(U,$J,358.3,16156,1,4,0)
 ;;=4^L68.0
 ;;^UTILITY(U,$J,358.3,16156,2)
 ;;=^5009262
 ;;^UTILITY(U,$J,358.3,16157,0)
 ;;=M80.00XA^^88^872^2
 ;;^UTILITY(U,$J,358.3,16157,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16157,1,3,0)
 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,16157,1,4,0)
 ;;=4^M80.00XA
 ;;^UTILITY(U,$J,358.3,16157,2)
 ;;=^5013363
 ;;^UTILITY(U,$J,358.3,16158,0)
 ;;=M81.0^^88^872^3
 ;;^UTILITY(U,$J,358.3,16158,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16158,1,3,0)
 ;;=3^Age-Related Osteoporosis w/o Fx
 ;;^UTILITY(U,$J,358.3,16158,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,16158,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,16159,0)
 ;;=M85.80^^88^872^26
 ;;^UTILITY(U,$J,358.3,16159,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16159,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,16159,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,16159,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,16160,0)
 ;;=N62.^^88^872^5
 ;;^UTILITY(U,$J,358.3,16160,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16160,1,3,0)
 ;;=3^Gynecomastia
 ;;^UTILITY(U,$J,358.3,16160,1,4,0)
 ;;=4^N62.
 ;;^UTILITY(U,$J,358.3,16160,2)
 ;;=^5015790
 ;;^UTILITY(U,$J,358.3,16161,0)
 ;;=E66.3^^88^872^27
 ;;^UTILITY(U,$J,358.3,16161,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16161,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,16161,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,16161,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,16162,0)
 ;;=E89.1^^88^872^31
 ;;^UTILITY(U,$J,358.3,16162,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16162,1,3,0)
 ;;=3^Postprocedural Hypoinsulinemia
 ;;^UTILITY(U,$J,358.3,16162,1,4,0)
 ;;=4^E89.1
 ;;^UTILITY(U,$J,358.3,16162,2)
 ;;=^5003036
 ;;^UTILITY(U,$J,358.3,16163,0)
 ;;=R73.03^^88^872^33
 ;;^UTILITY(U,$J,358.3,16163,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16163,1,3,0)
 ;;=3^Pre-Diabetes
 ;;^UTILITY(U,$J,358.3,16163,1,4,0)
 ;;=4^R73.03
 ;;^UTILITY(U,$J,358.3,16163,2)
 ;;=^8295662
 ;;^UTILITY(U,$J,358.3,16164,0)
 ;;=E73.9^^88^872^18
 ;;^UTILITY(U,$J,358.3,16164,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16164,1,3,0)
 ;;=3^Lactose Intolerance,Unspec
 ;;^UTILITY(U,$J,358.3,16164,1,4,0)
 ;;=4^E73.9
 ;;^UTILITY(U,$J,358.3,16164,2)
 ;;=^5002914
 ;;^UTILITY(U,$J,358.3,16165,0)
 ;;=H40.9^^88^873^11
 ;;^UTILITY(U,$J,358.3,16165,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16165,1,3,0)
 ;;=3^Glaucoma,Unspec
 ;;^UTILITY(U,$J,358.3,16165,1,4,0)
 ;;=4^H40.9
 ;;^UTILITY(U,$J,358.3,16165,2)
 ;;=^5005931
 ;;^UTILITY(U,$J,358.3,16166,0)
 ;;=H26.9^^88^873^7
 ;;^UTILITY(U,$J,358.3,16166,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16166,1,3,0)
 ;;=3^Cataract,Unspec
 ;;^UTILITY(U,$J,358.3,16166,1,4,0)
 ;;=4^H26.9
 ;;^UTILITY(U,$J,358.3,16166,2)
 ;;=^5005363
